Hemolytic Uremic Syndrome with Clopidogrel after Coronary Angioplasty / 대한내과학회지
Korean Journal of Medicine
;
: S253-S257, 2011.
Article
in Korean
| WPRIM
| ID: wpr-152518
ABSTRACT
Thienopyridines are antiplatelet agents used in post-percutaneous coronary angioplasty patients and patients with acute coronary syndrome, stroke, and peripheral arterial disease. Ticlopidine has been shown to reduce the incidence of stent thrombosis, but it may also cause serious hematological side effects. Among the thienopyridines, clopidogrel is considered to be a safe alternative to ticlopidine because of its decreased incidence of hematological adverse effects. However, some hematological side effects can occur and may be fatal. In this case, a 47-year-old man complained of dyspnea and generalized edema. He had been taking clopidogrel after coronary angioplasty. His laboratory findings showed acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia, which were consistent with hemolytic uremic syndrome (HUS). After discontinuing clopidogrel and undergoing plasma exchange, he recovered fully. To our knowledge, this is the first reported case of clopidogrel-induced HUS in Korea.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Plasma Exchange
/
Thrombocytopenia
/
Thrombosis
/
Ticlopidine
/
Platelet Aggregation Inhibitors
/
Stents
/
Incidence
/
Angioplasty
/
Stroke
/
Dyspnea
Type of study:
Incidence study
/
Prognostic study
Limits:
Humans
Country/Region as subject:
Asia
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS